University of Dundee, MSc Human Clinical Embryology and Assisted Conception - Apply now for September 2018
Page URL: https://www.bionews.org.uk/page_94253

Cancer-killing cells work well in mice

19 August 2013
Appeared in BioNews 718

Human stem cells have been reprogrammed to form cancer-targeting immune cells that were shown to stop tumour growth in mice.

Scientists generated induced pluripotent stem cells (iPS cells) from white blood cells known as T-lymphocytes, then reprogrammed these to become cancer-specific T-cells that were able to multiply into large numbers in the laboratory.

Immunotherapy – where immune cells are taken from the blood, multiplied and injected back into the body – shows promise as a treatment for cancer. However, finding enough T-cells, immune cells that can kill cancer cells while ignoring healthy ones, is rare, particularly in people whose immune system is already low as a result of cancer. This approach could mean that unlimited numbers of T-cells could be produced in the laboratory and targeted at a specific type of tumour.

The researchers, from the Memorial Sloan-Kettering Cancer Centre, USA, wrote: 'In summary, the combination of... technologies that we describe here offers a potential new source of off-the-shelf T-cells of pre-determined antigen specificity'.

The study makes use of two techniques – generating iPS cells in the lab and converting these to form T-cells, and then genetically modifying them to target cancer cells, known as chimeric antigen receptor (CAR) technology.

'By combining the CAR technology with the iPS technology, we can make T cells that recognise X, Y, or Z', Dr Michel Sadelain, who led the study, told The Scientist. 'There's flexibility here for redirecting their specificity towards anything that you want'.

The T lymphocytes are directed towards CD19, a protein generated by malignant cells. When tested in mice with lymphoma, the T-cells were seen to 'potently inhibit tumour growth', said the study.

'This is very specific to the cancer cells themselves. This means fewer side effects and secondly, because they stay in the body, they are 'living drugs' and once present move around and stop recurrences', Dr Sadelain told the Express.

'It looks pretty exciting. It's effectively using the body's own immune system and harnessing its power to attack the cancer cells', Dr Emma Smith, senior science information officer at Cancer Research UK, told the Express.

The study was published in Nature.

SOURCES & REFERENCES
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
Nature Biotechnology |  11 August 2013
New hope for cancer cure
The Express |  12 August 2013
Stem cell technology can mass-produce cancer-killing cells to target tumours
Mirror |  11 August 2013
Tumor-Targeting T Cells Engineered
The Scientist |  11 August 2013
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
2 March 2015 - by Dr Linda Wijlaars 
This well-timed Panorama documentary details how innovative treatments are being developed at the Institute of Cancer Research and trialled at the Royal Marsden...

19 May 2014 - by Antony Blackburn-Starza 
British pharmaceutical company AstraZeneca has presented trial data from an experimental lung cancer drug...
24 February 2014 - by Chris Hardy 
Researchers trialling a gene therapy-based treatment for leukemia have said the early results go beyond anything they could have thought of in their 'wildest dreams'...
22 July 2013 - by Holly Rogers 
For the first time, scientists have created induced pluripotent stem cells from adult tissue without adding extra genes...
7 January 2013 - by Dr Greg Ball 
Immune cells that can recognise and kill cancer cells have been grown from induced pluripotent stem cells (iPSCs)...
12 October 2009 - by Dr Will Fletcher 
Stem cells could potentially be used to vaccinate people against colon cancer. This surprising conclusion was made by researchers from China and the US after laboratory mice immunised with human embryonic stem (ES) cells experienced a dramatic decline in tumour growth compared to control mice. The idea that embryonic material may generate an anti-tumour response is an old one, but one that has never been tested outside animal research, so to find such an effect wit...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.